


In the Claims:


Claims 1 to 34 (cancelled).

Claim 35 (currently amended) A compound of the formula




(I)_G

in racemic, enantiomeric form or any combination of these forms, in which Het is a heterocycle with 5 members consisting of 2 heteroatoms and such that formula (I)_G is:



(I)_{G1}


or



(I)_{G2}

in which

A is



in which Q is $-OR^{22}$ and R^{22} is hydrogen

and R^{19} , R^{20} and R^{21} are hydrogen or alkyl or alkyl,

X is $-S-$,

R^1 and R^2 are hydrogen or alkyl,

B is hydrogen,

Ω is $NR^{46}R^{47}$,

R^{46} and R^{47} are hydrogen;

n, each time that they occur, is independently an integer from 0 to 6;

and its pharmaceutically acceptable salts.

Claim 36 (cancelled).

Claim 37 (previously presented) The compound of claim 35 or its salt,
wherein n is an integer from 0 to 2.

Claim 38 (previously presented) The compound of claim 37 or its salt,
wherein R_1 and R_2 are hydrogen.

Claim 39 (previously presented) The compound of claim 37 or its salt,
wherein R_1 is hydrogen and R_2 is alkyl.

Claim 40 (cancelled).

Claim 41 (previously presented) A pharmaceutical composition comprising a compound of claim 35 and at least one pharmaceutically acceptable excipient.

Claim 42 (cancelled).

Cancel **Claim 43**.

Claims 44 to 48 (cancelled).

Claim 49 (previously presented) A compound of claim 35 wherein n is 0.

Add the following claims:

Claim 50 (new) A compound of claim 35 which is 4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-di(tert-butyl)-phenol.

Claim 51 (new) The pharmaceutical composition of claim 41 wherein the compound is 4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-di(tert-butyl)phenol.